LY-02404
- Generic Name
- LY-02404
CCTA-Guided Lipid Management Strategy Trial in Asymptomatic Individuals
• The RESPECT2 trial is evaluating a CCTA-guided strategy for lipid management versus usual care in asymptomatic individuals aged 40-69 in Nanjing, China.
• The primary outcome measures the proportion of participants regularly taking lipid-lowering medication at 6 and 12 months.
• Secondary outcomes include the proportion achieving LDL-C targets, changes in TC and LDL-C levels, and cardiovascular events.
• The study aims to determine the prevalence of subclinical CAD and assess the impact of CCTA on adherence to lipid-lowering medication.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath